Cyclophosphamide
Head and Neck Small Cell Carcinoma
Thomas Jefferson UniversitySmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Head and Neck Small Cell Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Epirubicin Thomas Jefferson University | Phase 2 | B |
Definity Thomas Jefferson University | Phase 1 | CC |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →